Electra IPO: Shares of the developer of treatments for immune disorders and cancer are now available

Pre-market trading in shares of Electra Therapeutics, a drug developer, has begun on the Freedom client trading platform. This biotechnology company has products already in the final stages of clinical trials. It develops drugs for cancer and immune disorders that specifically target certain regulatory proteins, according to Reuters. Later on September 18, Electra Therapeutics shares will begin trading on the Nasdaq under the ticker symbol ETRA.

Electra Therapeutics successfully raised $350 million in its IPO. It sold 23.3 million shares at $15 per share, which is in the middle of the previously announced price range ($14–16). Based on the IPO results, the company’s total valuation can be estimated at $941.5 million, according to Bloomberg.

The listing was organized by Jefferies, TD Cowen, Evercore ISI, and Cantor.

In October and June, Electra raised approximately $182.7 million in a Series C funding round led by a division of the French pharmaceutical company Sanofi, as well as OrbiMed Advisors and the Redmile Group. According to a filing with the U.S. Securities and Exchange Commission (SEC), as of June 30 of this year, the company had $97.7 million in cash and cash equivalents.

The company, headquartered in San Francisco, has been in operation since 2018, according to Fierce Biotech. It is developing a therapy that targets SIRP receptors—special regulatory proteins on the surface of immune cells that act as a “brake” on an overactive immune system, Reuters notes. As of June 30, the company had 46 employees, but it plans to expand its workforce, according to a filing with the SEC.

Electra Therapeutics’ flagship drug is ipsoprubart. It neutralizes dangerous immune cells that lead to a severe condition known as secondary hemophagocytic lymphohistiocytosis: a rare, life-threatening hyperinflammatory syndrome in which the immune system becomes overactive and damages the body. Cancer, infections, autoimmune diseases, and immunotherapy can all trigger this syndrome, which requires immediate intervention, according to Fierce Biotech.

The drug is currently undergoing large-scale international trials to obtain official approval for use, according to Reuters. The drug has been granted “breakthrough therapy” status by the U.S. Food and Drug Administration (FDA), which expedites the development and testing process, adds Bloomberg.

Electra plans to use the proceeds from the IPO to fund clinical trials of ipsoprubart, advance its second drug candidate, ELA822, and to replenish working capital and meet other corporate needs.

Electra’s plans to go public come at a time when a growing number of biotech companies are entering the public market, according to Fierce Biotech. This year, these companies have raised a total of $6.8 billion through IPOs in the U.S., according to Bloomberg. These offerings yielded an average return of nearly 70%. The leader was Veradermics, a developer of a treatment for alopecia areata, whose stock has risen approximately five to six times since its listing in February.

“Biotech IPOs serve as a barometer of the sector’s health, and the average amount of capital raised in the U.S. in 2026—$329 million—is the highest since 2018, significantly surpassing the results of recent strong years. This points to a strong finish to the year, when the number of listings could reach 30,” noted Bloomberg Intelligence analysts Sam Fazeli and Cindy Wu.

Electra’s financial metrics for 2024 and 2025 are typical for biotech startups in the research phase: there is no revenue yet, but there are massive costs for development and administrative expenses, said Donovan Jones, an analyst at IPO Edge, in a comment to Seeking Alpha.

According to him, the main risks include the unpredictability of drug trials and the need for new funding. Another point to note: the company has been granted “small startup” status, so by law it is not required to share all internal information with investors. The stock of such secretive companies often falls after going public, but this usually applies to firms in other sectors, not medical projects, Jones clarifies.

Freedom Finance analyst Alem Bektemirov estimates the company’s stock has growth potential of approximately 40% relative to its $15 offering price. The expert believes that the main risks for Electra include a lack of revenue from products that are still in the development stage, regulatory risks related to regulatory approvals, and the need for additional capital to further finance development. If the company is unable to raise the necessary funds, it may postpone or discontinue certain programs, Bektemirov notes.

___________________

Freedom clients will be able to trade Electra Therapeutics shares before the main trading session begins. Trading will begin in the early pre-market session 2–3 hours before the U.S. markets open (from 3:30 p.m. to 4:30 p.m. Astana time). To participate, click on the ETRA ticker.

This article was AI-translated and verified by a human editor